[Table_Main] 行业研究|可选 消费|汽车与汽车零部件 证 券研究报告 汽车与汽车零部件行业 2024年05月12日 周报、月报 [Table_Invest] [T4ab月le_T产itl销e] 快速增长，结构替换持续推进 推荐|维持 [报Ta告bl要e_S点um：ma ry] [过T去ab一le年_P市ic场Qu行ot情e]  4月汽车产销快速增长，全年销量基础稳固 17% 2024年4月，中汽协口径汽车产销分别完成240.6万辆和235.9万辆， 8% 同比镇长12.8%和9.3%。1-4月，汽车产销分别完成901.2万辆和907.9 -1% 万辆，同比分别增长7.9%和10.2%。其中乘用车产销分别完成204.8万 -10% 辆和200.1万辆。同比分别增长15.2%和10.5%。1-4月乘用产销分别完 -19% 成 765.8 万辆和 768.9 万辆，同比分别增长 8.6%和10.6%。4 月淡季汽 5/12 8/11 11/10 2/9 5/10 车产销整体仍然保持较高增速，为全年销量增长打下坚实基础。 汽车与汽车零部件 沪深300  燃油车快速收缩，新能源+海外提供增长动能 资料来 ...

[Table_Main] 行 业研究|电信服务 证 券研究报告 电信服务行业周报 2024年05月12日 [TOabplee_nTiAtleI] 将发布产品更新，关注硬件及应用端催化 [Table_Invest] 推荐|维持 ——通信行业周报 [Table_Summary] 报告要点： [过Ta去bl一e_年Pic市Q场uo行te]情  市场整体行情及通信细分板块行情回顾 周行情：本周（2024.05.06-2024.05.10）上证综指上涨 1.60%，深 沪深300 通信(申万) 证成指上涨1.50%，创业板上涨1.06%。本周申万通信回调3.15%。 40% 考虑通信行业的高景气度延续，AI、5.5G 及卫星通信持续推动行业 20% 发展，我们给予通信行业“推荐”评级。 0% 细分行业方面：本周（2024.05.06-2024.05.10）通信板块三级子行 -20% 业中，通信线缆及配套上涨幅度最高，涨幅为2.16%，通信网络设备 -40%5/13 8/13 11/13 2/13 及器件回调幅度最高，跌幅为5.90%，本周各细分板块主要呈回调趋 势。 资料来源：Wind，国元证券研究所 个股方面：本周 ...

行业比较跟踪：出口和出海的景气在上升 在今年的五一假期，国内旅游出游人次同比增长 7.6%，较 2019 年同期 增长 28.2%；出游总花费同比增长 12.7%，按可比口径较 2019 年同期增长 13.5%。 旅游的景气虽高，但二阶也许大致见顶： （1）如果以 2019 年为对标的话，在去年十一及春节旅游连续两次假期中， 人均消费都超过了 2019 年同期，但这次五一假期的人均旅游消费再次低于 2019 年同期（今年五一旅游人均消费为 565.73 元/人，2019 年同期为 603.44 元/人）； （2）从最近的连续几次假期旅游消费看，人均消费的水平变化在变平； （3）刨除春节月份的话，刚刚公布的 CPI 旅游分项数据跌至 2023 年以来最 低，虽然还在原先的上升轨道中，但比起年初时，确实价格出现了幅度稍大 的回撤。 出口其实迈过了最困难的时候，现在正在波动改善的过程中，在 3 月出 口不及预期后，4 月的出口数据再次出现了反弹，今年的累计出口速度也超过 了去年。 往后看，出口的景气应会延续，这个趋势首先来自于周期的变化，自全 2024 年 05 月 11 日 [Table_PicStock] 主要 ...

Investment Rating - The report initiates coverage on Grand Pharmaceutical Group (0512 HK) with a "Buy" rating [6] Core Views - Grand Pharmaceutical Group is a long-established pharmaceutical company with three major business segments: pharmaceutical technology, nuclear medicine oncology, and precision cardiovascular intervention technology, along with biotech [2] - The company achieved revenue of HKD 10 53 billion in 2023, a 10 12% YoY increase, with net profit attributable to shareholders of HKD 1 88 billion, a 9 59% YoY decline [2] - The nuclear medicine oncology segment is expected to drive rapid growth, while the cardiovascular and respiratory segments are projected to maintain stable growth [6] - Revenue is forecasted to reach HKD 12 00 billion in 2024, HKD 13 92 billion in 2025, and HKD 15 32 billion in 2026, with EPS of HKD 0 64, HKD 0 68, and HKD 0 73 respectively [6] Business Segments Nuclear Medicine Oncology - The company is actively expanding its nuclear medicine oncology pipeline, with its flagship product Y-90 microspheres (Yigantai®) showing significant efficacy in treating primary liver cancer and colorectal cancer liver metastases [3] - Colorectal cancer is the third most common cancer globally, accounting for 10% of all cancer cases, while liver cancer is highly prevalent in China, with 47% of global new cases in 2018 [3] - Yigantai® has been approved for colorectal cancer liver metastases and is expected to gain approval for primary liver cancer soon, becoming a key growth driver [3] - The company has 14 innovative nuclear medicine products in its pipeline, including 9 RDC (radiopharmaceutical drug conjugate) products, with 4 in clinical trials in China [29] Precision Cardiovascular Intervention - The company entered the cardiovascular medical device field in 2015 through acquisitions and has built a comprehensive platform covering coronary, peripheral, structural heart, and electrophysiology [4] - Key products include drug-coated balloons (DCB), Novasight Hybrid intravascular imaging system, and HeartLightX3 laser ablation platform [4] - The DCB market in China is expected to grow from RMB 4 39 billion in 2019 to RMB 8 38 billion in 2024, driven by aging population and policy support [52] - The electrophysiology device market in China is projected to reach RMB 15 7 billion by 2025, with HeartLightX3 showing promising potential [57] Traditional Business Segments - The company has a strong presence in traditional segments such as cardiovascular emergency, ophthalmology, respiratory, and biotech products, with stable market share and brand influence [5] - In ophthalmology, products like polyethylene alcohol eye drops and He Xue Ming Mu tablets have shown steady sales growth [61] - The respiratory segment includes products like Xiao Qing Zao enteric-coated soft capsules, which have maintained a strong market position [61]

行业研究报告 发布时间：2024年5月8日 电动市场需求深化，智能生态加速赋能 ——新能源汽车行业专题报告 ...

Investment Rating - The report maintains a "Buy" rating for Huakang Medical (301235.SZ) [4][9][14] Core Views - Huakang Medical reported a revenue of 1.6 billion (up 34.7%) for 2023, primarily driven by its medical purification system integration business and medical consumables sales. The net profit attributable to shareholders was 110 million (up 4.7%) [9] - In Q1 2024, the company achieved a revenue of 230 million (down 4.4%) and a net loss of 32 million (down 85.3%), attributed to high personnel growth and operational cost increases [9] - The core business of medical purification integration continues to grow rapidly, with significant increases in sales expenses and R&D investments [9] Financial Summary - Revenue Forecast: - 2024E: 2.09 billion (up 30.4%) - 2025E: 2.62 billion (up 25.28%) - 2026E: 3.23 billion (up 23.34%) [3][9] - Net Profit Forecast: - 2024E: 158 million (up 46.86%) - 2025E: 210 million (up 33.22%) - 2026E: 284 million (up 35.16%) [3][9] - Earnings Per Share (EPS): - 2024E: 1.49 - 2025E: 1.99 - 2026E: 2.69 [3][9] - Price-to-Earnings (P/E) Ratio: - 2024E: 13.57 - 2025E: 10.19 - 2026E: 7.54 [3][9] Business Strategy - The company focuses on a "two main, three auxiliary" strategy, aiming to establish itself as a benchmark in the medical purification industry. It has secured significant contracts and awards, enhancing its reputation in the market [9] - As of the end of 2023, the company had a backlog of orders amounting to 2.21 billion, primarily in the medical purification integration business [9]

Investment Rating - The report maintains a "Buy" rating for the company [2][17]. Core Views - The company's core business shows steady growth, with a focus on digital upgrades that are expected to yield positive results in the future [2]. - In 2023, the company achieved a revenue of 11.244 billion yuan, a slight decrease of 3.79% year-on-year, while the net profit attributable to shareholders increased by 32.21% to 936 million yuan [2]. - The company has actively engaged in shareholder returns through dividends, distributing 3.05 yuan per 10 shares [2]. Summary by Relevant Sections Financial Performance - In 2023, the company's revenue was 11.244 billion yuan, with a net profit of 936 million yuan, reflecting a year-on-year increase of 32.21% [2]. - The first quarter of 2024 saw a revenue of 2.929 billion yuan, down 5.44% year-on-year, with a net profit of 293 million yuan [2]. - The gross profit margin for the core business improved, with the educational materials segment achieving a revenue of 1.751 billion yuan, up 2.43% year-on-year [2]. Business Development - The company is enhancing its supply chain services and integrating online and offline bookstore operations, covering 200 stores and serving 420,000 users, a 203% increase year-on-year [2]. - The logistics service segment generated a revenue of 3.798 billion yuan, a slight decrease of 3.54% year-on-year, while the educational research segment saw a remarkable growth of 607.33% in sales revenue [2]. Future Outlook - The company is expected to benefit from its focus on AI and smart education, with projected net profits of 775 million yuan, 969 million yuan, and 1.148 billion yuan for 2024, 2025, and 2026 respectively [2]. - Earnings per share (EPS) are forecasted to be 0.39 yuan, 0.49 yuan, and 0.58 yuan for the same years, with corresponding price-to-earnings ratios of 19, 15, and 13 times [2].

[Table_Main] 公司研究|医疗保健|制药、生物科技与生命科学 证券研究报告 [Table_TargetPrice] 药康生物(688046)公司点评报告 2024 年 05 月 11 日 [Table_Title] 收入保持稳健增长，看好未来业绩增长 ——药康生物(688046.SH)2023 年报及 2024 年一季度报告点评 [Table_Summary] 事件： 药康生物于近日发布 2023 年报及 2024 年一季度报告：2023 年公司实现 收入 6.2 亿（+20.5%），主要系公司业务持续快速发展，其中商品化模型销 售业务和功能药效业务收入分别同比增长 13.6%和 36.1%，归母净利润 1.6 亿（-3.5%），扣非归母净利润 1.1 亿（+5.0%），主要系公司目前仍处业务 扩张期，持续高强度研发投入、加大海外市场开拓力度、生产人员扩招、新 产能投产后折旧摊销增加等原因致使公司利润短期承压。2024Q1 公司实现 收入 1.6 亿（+12.0%）、归母净利润 2948.0 万（-5.1%），扣非归母净利润 2286.8 万（+2.7%）。 公司持续高强度投入研发，"野化鼠"、"药 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Views - The company has achieved significant revenue growth, with 2023 revenue reaching 930 million (up 37.8%) and a net profit of 180 million (up 18.1%) [2][3]. - The company has established a comprehensive "preclinical + clinical" drug development service platform, enhancing its competitive advantage and customer retention [4]. - The company has a robust order backlog of 2.57 billion (up 28.7% year-on-year), indicating strong future revenue potential [2][3]. Financial Performance - In Q1 2024, the company reported revenue of 250 million (up 8.5%) and a net profit of 72.75 million (up 51.8%) [2][3]. - The company achieved a per capita output value of 747,000 (up 14.6% year-on-year) in 2023 [3]. - The company has initiated over 100 new self-research projects in 2023, bringing the total to over 350 projects [3]. Profit Forecast - Revenue growth rates are projected at 32.63%, 31.66%, and 30.61% for 2024, 2025, and 2026, respectively [4]. - Net profit growth rates are expected to be 39.10%, 36.71%, and 34.92% for the same years [4]. - Earnings per share (EPS) are forecasted to be 2.29, 3.14, and 4.23 yuan per share for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 24.34, 17.80, and 13.20 [4].

Investment Rating - The report maintains a "Buy" rating for the company BlueFocus (300058) [1][9] Core Insights - The company reported a revenue of 52.62 billion yuan in 2023, a year-on-year increase of 43.44%, and a net profit attributable to shareholders of 117 million yuan, marking a 105.36% increase year-on-year, thus turning profitable [9] - The company has shown strong growth in its overseas advertising business, with a revenue increase of 41.69% [9] - The implementation of the "AI²" strategy has led to significant improvements in operational efficiency, with overall business productivity increasing by approximately 50% [9] Financial Summary - Revenue Forecast: The company is expected to achieve revenues of 63.14 billion yuan in 2024, 70.37 billion yuan in 2025, and 77.41 billion yuan in 2026 [2][4] - Net Profit Forecast: The net profit attributable to shareholders is projected to be 366 million yuan in 2024, 496 million yuan in 2025, and 631 million yuan in 2026 [4][9] - Earnings Per Share (EPS): EPS is expected to be 0.15 yuan in 2024, 0.20 yuan in 2025, and 0.25 yuan in 2026 [4][9] - Price-to-Earnings Ratio (P/E): The P/E ratio is projected to be 42 in 2024, 31 in 2025, and 25 in 2026 [4][9] Business Performance - The company’s advertising services, including comprehensive promotion and advertising agency services, have shown significant revenue growth, with the comprehensive promotion service revenue reaching 11.28 billion yuan, a 73.05% increase [9] - The overseas advertising business has been a key growth driver, with revenue from Meta and Google advertising maintaining double-digit growth rates [9] Strategic Initiatives - The company has fully implemented the "AI + Human" work model, achieving 100% coverage among employees, which has significantly enhanced creative capabilities [9] - The company has developed nearly 300 AI marketing cases, generating an AI-driven revenue of 108 million yuan in 2023 [9]